title: [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
abstract: Primary antibody deficiency (PAD) is the most common form of primary immunodeficiency (PID), and presents up to 60-70% of PID. The hallmark of PAD are low antibody level and recurrent infections. Patients require life-long immunoglobulin replacement therapy. Now they can be treated either with intravenous (IVIG) or subcutaneous (SCIG) immunoglobulin. The last one is indicated in patients with unacceptable adverse reactions to the intravenous immunoglobulin preparations, with poor vein access or willing to improve the quality of their life. Several data and clinical trials proved that SCIG therapy is at least as safe and efficacious as IVIG to prevent infections in patients with PAD.
authors.affiliation: Oddział Immunologii, Instytut "Pomnik-Centrum Zdrowia Dziecka" w Warszawie. oddzial.immunologia@czd.pl
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Pac
mesh_terms: D002648:Child; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage* / Q000097:blood; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy* / Q000276:immunology; D007279:Injections, Subcutaneous
chemical_list: D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous